COVID-19 is a pandemic that is greatly increasing the number of patients undergoing respiratory distress worldwide across all age groups.
The FDA has granted Emergency Use Authorization (EUA) for use of the life-saving Vayu-bCPAP device to help in the fight against COVID-19. This clears the way for worldwide distribution of these novel ultra-low cost, portable, electricity-free bCPAP devices.
Vayu-bCPAP can be used for most newborn and infant cases requiring respiratory support instead of invasive ventilators.
Thus, there is a dual role for the Vayu-bCPAP device:
(1) Free up ventilators for adult COVID-19 patients by providing a better, alternative treatment for newborns and other infants who are currently undergoing CPAP using ventilators
(2) Directly support newborns and infants with acute respiratory distress from COVID-19, Respiratory Distress Syndrome, pneumonia, among other causes of acute respiratory failure.